Amgen, Inc. (NASDAQ:AMGN) Shares Acquired by PFG Advisors

PFG Advisors grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 11.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,390 shares of the medical research company’s stock after acquiring an additional 1,089 shares during the quarter. PFG Advisors’ holdings in Amgen were worth $2,044,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. grew its position in Amgen by 3.4% in the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after acquiring an additional 1,585,911 shares in the last quarter. Morgan Stanley grew its position in Amgen by 0.5% in the 2nd quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after acquiring an additional 34,674 shares in the last quarter. Nuveen Asset Management LLC grew its position in Amgen by 1,334.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after acquiring an additional 4,598,329 shares in the last quarter. Nordea Investment Management AB grew its position in Amgen by 5.0% in the 1st quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock valued at $894,700,000 after acquiring an additional 225,485 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Amgen by 9.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after acquiring an additional 239,576 shares in the last quarter. 76.32% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have weighed in on the company. BMO Capital Markets set a $240.00 target price on Amgen and gave the company a “buy” rating in a research report on Monday, September 30th. Morgan Stanley dropped their target price on Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research report on Monday, July 15th. Piper Jaffray Companies lifted their target price on Amgen from $210.00 to $218.00 and gave the company an “overweight” rating in a research report on Monday, August 26th. Mizuho reaffirmed a “hold” rating and issued a $212.00 target price on shares of Amgen in a research report on Sunday, September 29th. Finally, Citigroup reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, August 12th. Eleven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $217.41.

In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $193.58, for a total transaction of $387,160.00. Following the completion of the sale, the director now owns 16,436 shares in the company, valued at $3,181,680.88. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the sale, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,851 shares of company stock valued at $3,671,900. 0.25% of the stock is owned by company insiders.

Shares of AMGN traded up $0.52 during midday trading on Tuesday, hitting $203.41. The company had a trading volume of 59,578 shares, compared to its average volume of 2,233,010. The company’s 50-day simple moving average is $199.57 and its 200-day simple moving average is $186.50. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. The firm has a market capitalization of $120.42 billion, a P/E ratio of 14.12, a P/E/G ratio of 2.61 and a beta of 1.11. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $211.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.58 by $0.39. The business had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.83 EPS. Equities analysts predict that Amgen, Inc. will post 14.31 earnings per share for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Penny Stocks

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.